Hakim Bouterfa

2.9k total citations
40 papers, 2.4k citations indexed

About

Hakim Bouterfa is a scholar working on Epidemiology, Oncology and Molecular Biology. According to data from OpenAlex, Hakim Bouterfa has authored 40 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Epidemiology, 15 papers in Oncology and 14 papers in Molecular Biology. Recurrent topics in Hakim Bouterfa's work include Neuroendocrine Tumor Research Advances (18 papers), Neuroblastoma Research and Treatments (12 papers) and Lung Cancer Research Studies (12 papers). Hakim Bouterfa is often cited by papers focused on Neuroendocrine Tumor Research Advances (18 papers), Neuroblastoma Research and Treatments (12 papers) and Lung Cancer Research Studies (12 papers). Hakim Bouterfa collaborates with scholars based in Germany, United States and Switzerland. Hakim Bouterfa's co-authors include K. Roosen, Detlef Doenecke, Larry K. Kvols, François Jamar, Raffaella Barone, Roelf Valkema, Eric P. Krenning, Jens Kaufmann, Damian Wild and Melpomeni Fani and has published in prestigious journals such as Journal of Clinical Oncology, The EMBO Journal and European Journal of Biochemistry.

In The Last Decade

Hakim Bouterfa

40 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hakim Bouterfa Germany	23	1.1k	1.0k	709	573	491	40	2.4k
Alessandra Pattarozzi Italy	31	371 0.3×	815 0.8×	162 0.2×	1.0k 1.8×	62 0.1×	51	2.1k
Ida Rapa Italy	27	580 0.5×	1.1k 1.0×	329 0.5×	828 1.4×	49 0.1×	66	2.5k
Hans‐Georg Wirsching Switzerland	19	429 0.4×	203 0.2×	275 0.4×	662 1.2×	215 0.4×	43	1.8k
Lyndon Kim United States	19	286 0.3×	412 0.4×	370 0.5×	756 1.3×	349 0.7×	42	2.4k
Andrew M. Donson United States	35	456 0.4×	632 0.6×	552 0.8×	1.7k 2.9×	37 0.1×	112	3.0k
Andreas M. Stark Germany	24	340 0.3×	850 0.8×	203 0.3×	681 1.2×	243 0.5×	47	2.4k
Piera Mondellini Italy	25	209 0.2×	1.0k 1.0×	149 0.2×	1.3k 2.3×	85 0.2×	37	2.6k
H. S. Friedman United States	21	154 0.1×	627 0.6×	454 0.6×	907 1.6×	568 1.2×	50	2.4k
Ho‐Shin Gwak South Korea	22	413 0.4×	343 0.3×	202 0.3×	502 0.9×	64 0.1×	84	1.6k
L. Magnus Bäcklund Sweden	20	260 0.2×	473 0.5×	403 0.6×	848 1.5×	204 0.4×	35	2.2k

Countries citing papers authored by Hakim Bouterfa

Since Specialization

Citations

This map shows the geographic impact of Hakim Bouterfa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hakim Bouterfa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hakim Bouterfa more than expected).

Fields of papers citing papers by Hakim Bouterfa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hakim Bouterfa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hakim Bouterfa. The network helps show where Hakim Bouterfa may publish in the future.

Co-authorship network of co-authors of Hakim Bouterfa

This figure shows the co-authorship network connecting the top 25 collaborators of Hakim Bouterfa. A scholar is included among the top collaborators of Hakim Bouterfa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hakim Bouterfa. Hakim Bouterfa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lawal, Ismaheel O., Gbenga O. Popoola, Johncy Mahapane, et al.. (2020). [68Ga]Ga-Pentixafor for PET Imaging of Vascular Expression of CXCR-4 as a Marker of Arterial Inflammation in HIV-Infected Patients: A Comparison with 18F[FDG] PET Imaging. Biomolecules. 10(12). 1629–1629. 13 indexed citations

Nicolas, Guillaume, Rosalba Mansi, Lisa McDougall, et al.. (2017). Biodistribution, Pharmacokinetics, and Dosimetry of ¹⁷⁷Lu-, ⁹⁰Y-, and ¹¹¹In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist ¹⁷⁷Lu-DOTATATE: The Mass Effect. Journal of Nuclear Medicine. 58(9). 1435–1441. 112 indexed citations

Nicolas, Guillaume, Seval Beykan, Hakim Bouterfa, et al.. (2017). Safety, Biodistribution, and Radiation Dosimetry of ⁶⁸Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study. Journal of Nuclear Medicine. 59(6). 909–914. 68 indexed citations

Beykan, Seval, Jan S. Dam, Uta Eberlein, et al.. (2016). 177Lu-OPS201 targeting somatostatin receptors: in vivo biodistribution and dosimetry in a pig model. EJNMMI Research. 6(1). 50–50. 16 indexed citations

Mercado, Moisés, Hakim Bouterfa, Tien‐Chun Chang, et al.. (2007). A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR^® (long‐acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clinical Endocrinology. 66(6). 859–868. 158 indexed citations

Valkema, Roelf, Stanislas Pauwels, Larry K. Kvols, et al.. (2006). Survival and Response After Peptide Receptor Radionuclide Therapy With [90Y-DOTA0,Tyr3]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors. Seminars in Nuclear Medicine. 36(2). 147–156. 234 indexed citations

Astruc, B, Peter Marbach, Hakim Bouterfa, et al.. (2005). Long‐Acting Octreotide and Prolonged‐Release Lanreotide Formulations Have Different Pharmacokinetic Profiles. The Journal of Clinical Pharmacology. 45(7). 836–844. 102 indexed citations

Bushnell, David, Yusuf Menda, Thomas M. O’Dorisio, et al.. (2004). Effects of Intravenous Amino Acid Administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher™]) Treatment. Cancer Biotherapy and Radiopharmaceuticals. 19(1). 35–41. 15 indexed citations

Helisch, Andreas, Helmut Reber, Hans‐Georg Buchholz, et al.. (2004). Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging. 31(10). 1386–92. 102 indexed citations

10.

Jamar, François, Raffaella Barone, Isabelle Mathieu, et al.. (2003). 86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. European Journal of Nuclear Medicine and Molecular Imaging. 30(4). 510–518. 177 indexed citations

11.

Bushnell, David, Yusuf Menda, Mark T. Madsen, et al.. (2003). Assessment of Hepatic Toxicity from Treatment with ⁹⁰ Y-SMT 487 (OctreoTher™) in Patients with Diffuse Somatostatin Receptor Positive Liver Metastases. Cancer Biotherapy and Radiopharmaceuticals. 18(4). 581–588. 10 indexed citations

12.

Bouterfa, Hakim, Thomas Picht, Christian Herbold, et al.. (2000). Retinoids Inhibit Human Glioma Cell Proliferation and Migration in Primary Cell Cultures But Not in Established Cell Lines. Neurosurgery. 46(2). 419–430. 73 indexed citations

13.

Bouterfa, Hakim, et al.. (1999). Expression of Different Extracellular Matrix Components in Human Brain Tumor and Melanoma Cells in Respect to Variant Culture Conditions. Journal of Neuro-Oncology. 44(1). 23–33. 43 indexed citations

14.

Drabent, Birgit, et al.. (1995). Isolation of two murine H1 histone genes and chromosomal mapping of the H1 gene complement. Mammalian Genome. 6(8). 505–511. 41 indexed citations

15.

Bouterfa, Hakim, F. Javier Piedrafita, Detlef Doenecke, & Magnus Pfahl. (1995). Regulation of H1° Gene Expression by Nuclear Receptors Through an Unusual Response Element: Implications for Regulation of Cell Proliferation. DNA and Cell Biology. 14(11). 909–919. 17 indexed citations

16.

Damke, Hanna, Hakim Bouterfa, & Thomas Braulke. (1994). Effects of insulin-like growth factor II on the generation of inositol trisphosphate, diacylglycerol and cAMP in human fibroblasts. Molecular and Cellular Endocrinology. 99(2). R25–R29. 9 indexed citations

17.

Eilers, Andreas, et al.. (1994). Role of a distal promoter element in the S‐phase control of the human H1.2 histone gene transcription. European Journal of Biochemistry. 223(2). 567–574. 10 indexed citations

18.

Doenecke, Detlef, Werner Albig, Hakim Bouterfa, & Birgit Drabent. (1994). Organization and expression of H1 histone and H1 replacement histone genes. Journal of Cellular Biochemistry. 54(4). 423–431. 76 indexed citations

19.

Bouterfa, Hakim, et al.. (1993). Differential regulation of the human H1°‐histone‐gene transcription in human tumor‐cell lines. European Journal of Biochemistry. 217(1). 353–360. 19 indexed citations

20.

Bouterfa, Hakim, Detlef Doenecke, & Monika Löffler. (1990). Increased level of histone H10 messenger RNA in hypoxic Ehrlich ascites tumor cells. Experimental Cell Research. 188(1). 160–163. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact